认知障碍中老年人群肌少症患病率的荟萃分析
BACKGROUND: Cognitive impairment, dementia and sarcopenia significantly reduce the quality of life in middle-aged and older adults by impairing daily functioning, making cognitive decline a major concern for healthcare professionals.…
要点
- 认知障碍中老年人肌少症合并患病率约30.1%,可能肌少症约40.5%。
- 65岁及以上认知障碍者肌少症患病率为32.7%。
- 患病率在社区为25.3%、医院为35.5%、机构为41.5%。
核心结论
- 约三分之一的认知障碍中老年人为肌少症患者,应重视早期识别与针对性干预。
研究设计与样本
- 检索Embase、Ovid MEDLINE、PubMed、CINAHL、Scopus和Web of Science六个数据库至2025年2月。
- 纳入队列研究和横断面研究,采用随机效应模型合并患病率。
主要发现
- 肌少症合并患病率为30.1%,可能肌少症合并患病率为40.5%。
- 65岁及以上成人中肌少症患病率为32.7%。
- 肌少症患病率按场所分别为社区25.3%、医院35.5%、机构41.5%。
- 年龄、女性、体质指数、共病及抑郁、糖尿病、高血压、营养不良、骨关节炎、饮酒和吸烟等风险因素为调节因素。
关键数值与推荐
- 认知障碍定义为记忆、注意和执行功能等认知功能下降,涵盖轻度认知障碍和痴呆。
- 肌少症定义为骨骼肌质量和功能下降,通过肌力或躯体功能评估。
临床怎么用
- 对认知障碍中老年人应早期筛查肌少症并给予针对性干预。
- 轻度认知障碍和痴呆个体是重点筛查与干预对象。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cognitive impairment, dementia and sarcopenia significantly reduce the quality of life in middle-aged and older adults by impairing daily functioning, making cognitive decline a major concern for healthcare professionals. OBJECTIVE: To estimate the prevalence of sarcopenia and probable sarcopenia in middle-aged and older adults with cognitive impairment. METHODS: Six databases-Embase, Ovid MEDLINE, PubMed, CINAHL, Scopus and Web of Science was conducted through February 2025. Cohort and cross-sectional studies included, and a random-effects model was used for pooled prevalence analysis. Cognitive impairment is a decline in cognitive functions, including memory, attention and executive function, covering mild cognitive impairment and dementia. Sarcopenia is decreased skeletal muscle mass and function, assessed by muscle strength or physical performance. RESULTS: A total of 67 studies involving 23 532 participants revealed a pooled sarcopenia prevalence of 30.1% and a probable sarcopenia prevalence of 40.5%. Additionally, amongst adults aged 65 and older, the prevalence of sarcopenia was 32.7%. The prevalence of sarcopenia varied by setting: 25.3% in community-dwelling populations, 35.5% in hospitals and 41.5% in institutional settings. Moderating factors included age, female, body mass index, comorbidities and risk factors such as depression, diabetes, hypertension, malnutrition, osteoarthritis, alcohol consumption and smoking. CONCLUSIONS: Approximately one-third of middle-aged and older adults with cognitive impairment demonstrate to have sarcopenia. Early detection and tailored interventions by public health professionals are crucial, particularly for individuals with mild cognitive impairment and dementia. Enhanced preventive strategies are essential to improving outcomes and reducing healthcare costs.
引用
- Ye JY, Chang LF, Chen R, et al. Prevalence of sarcopenia in middle-aged and older adults with cognitive impairment: a meta-analysis. Age Ageing. 2025. PMID: 40336206. doi:10.1093/ageing/afaf114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。